|Toxiciy Grade:||4||City/State/Province:||Tucson, AZ|
|Treatments:||Chemotherapy||Hospital:||University of Arizona Cancer Center|
Patients: This phase II study involved 97 women with stage III epithelial ovarian cancer.
Treatment: The treatment consisted of a chemotherapy drug called altretamine.
Toxicity: Grade 4 toxicities included neutropenia and anxiety/depression.
Results: Median survival was 57 months.
Support: The study was supported by a grant from MedImmune. This company manufactures or markets altretamine.
Correspondence: David S. Alberts, MD